Literature DB >> 23892536

The Goeckerman regimen for the treatment of moderate to severe psoriasis.

Rishu Gupta1, Maya Debbaneh, Daniel Butler, Monica Huynh, Ethan Levin, Argentina Leon, John Koo, Wilson Liao.   

Abstract

Psoriasis is a chronic, immune-mediated inflammatory skin disease affecting approximately 2-3% of the population. The Goeckerman regimen consists of exposure to ultraviolet B (UVB) light and application of crude coal tar (CCT). Goeckerman therapy is extremely effective and relatively safe for the treatment of psoriasis and for improving a patient's quality of life. In the following article, we present our protocol for the Goeckerman therapy that is utilized specifically at the University of California, San Francisco. This protocol details the preparation of supplies, administration of phototherapy and application of topical tar. This protocol also describes how to assess the patient daily, monitor for adverse effects (including pruritus and burning), and adjust the treatment based on the patient's response. Though it is one of the oldest therapies available for psoriasis, there is an absence of any published videos demonstrating the process in detail. The video is beneficial for healthcare providers who want to administer the therapy, for trainees who want to learn more about the process, and for prospective patients who want to undergo treatment for their cutaneous disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23892536      PMCID: PMC3735239          DOI: 10.3791/50509

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  15 in total

Review 1.  Duration of remission of psoriasis therapies.

Authors:  J Koo; M Lebwohl
Journal:  J Am Acad Dermatol       Date:  1999-07       Impact factor: 11.527

2.  Modern modified 'ultra' Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies.

Authors:  E Lee; J Koo
Journal:  J Dermatolog Treat       Date:  2005-04       Impact factor: 3.359

3.  Goeckerman treatment for remission of psoriasis refractory to biologic therapy.

Authors:  Rocco Serrao; Mark D P Davis
Journal:  J Am Acad Dermatol       Date:  2009-02       Impact factor: 11.527

4.  Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis.

Authors:  Rebeca de Miguel; Rokea el-Azhary
Journal:  Int J Dermatol       Date:  2009-06       Impact factor: 2.736

5.  Positive effect of modified Goeckerman regimen on quality of life and psychosocial distress in moderate and severe psoriasis.

Authors:  Erick Chern; Diana Yau; Ji-Chen Ho; Wei-Ming Wu; Cheng-Yu Wang; Hsueh-Wen Chang; Yu-Wen Cheng
Journal:  Acta Derm Venereol       Date:  2011-06       Impact factor: 4.437

6.  No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema.

Authors:  Judith H J Roelofzen; Katja K H Aben; Ursula T H Oldenhof; Pieter-Jan Coenraads; Hans A Alkemade; Peter C M van de Kerkhof; Pieter G M van der Valk; Lambertus A L M Kiemeney
Journal:  J Invest Dermatol       Date:  2009-12-17       Impact factor: 8.551

7.  Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study.

Authors:  M R Pittelkow; H O Perry; S A Muller; W Z Maughan; P C O'Brien
Journal:  Arch Dermatol       Date:  1981-08

8.  The Goeckerman regimen in two psoriasis day care centers.

Authors:  A Menter; D L Cram
Journal:  J Am Acad Dermatol       Date:  1983-07       Impact factor: 11.527

Review 9.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.

Authors:  Alan Menter; Neil J Korman; Craig A Elmets; Steven R Feldman; Joel M Gelfand; Kenneth B Gordon; Alice Gottlieb; John Y M Koo; Mark Lebwohl; Henry W Lim; Abby S Van Voorhees; Karl R Beutner; Reva Bhushan
Journal:  J Am Acad Dermatol       Date:  2009-10-07       Impact factor: 11.527

10.  Incidence of skin cancers in patients with atopic dermatitis treated with ocal tar. A 25-year follow-up study.

Authors:  W Z Maughan; S A Muller; H O Perry; M R Pittelkow; P C O'Brien
Journal:  J Am Acad Dermatol       Date:  1980-12       Impact factor: 11.527

View more
  4 in total

Review 1.  The Patient's Guide to Psoriasis Treatment. Part 4: Goeckerman Therapy.

Authors:  Tian Hao Zhu; Mio Nakamura; Benjamin Farahnik; Michael Abrouk; Rasnik K Singh; Kristina M Lee; Sarah Hulse; John Koo; Tina Bhutani; Wilson Liao
Journal:  Dermatol Ther (Heidelb)       Date:  2016-07-29

Review 2.  The Patient's Guide to Psoriasis Treatment. Part 3: Biologic Injectables.

Authors:  Michael Abrouk; Mio Nakamura; Tian Hao Zhu; Benjamin Farahnik; Rasnik K Singh; Kristina M Lee; Margareth V Jose; John Koo; Tina Bhutani; Wilson Liao
Journal:  Dermatol Ther (Heidelb)       Date:  2016-07-29

Review 3.  Phototherapy in dermatological maladies (Review).

Authors:  Daciana Elena Branisteanu; Diana Stefania Dirzu; Mihaela Paula Toader; Daniel Constantin Branisteanu; Alin Codrut Nicolescu; Ilarie Brihan; Camelia Margareta Bogdanici; George Branisteanu; Andreea Dimitriu; Nicoleta Anton; Elena Andrese Porumb
Journal:  Exp Ther Med       Date:  2022-02-03       Impact factor: 2.447

4.  Serum level of antibody against benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts in people dermally exposed to PAHs.

Authors:  Lenka Borska; Ctirad Andrys; Jan Krejsek; Vladimir Palicka; Marcela Chmelarova; Kvetoslava Hamakova; Jan Kremlacek; Pavel Borsky; Zdenek Fiala
Journal:  J Immunol Res       Date:  2014-04-13       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.